This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Novo Nordisk hit back at telehealth company Hims’ controversial Super Bowl comme...
Several brand-name drugmakers believe they will withstand any drug pricing impac...
Novo Nordisk hit back at telehealth company Hims’ controversial Super Bowl comme...
Boehringer Ingelheim said its experimental treatment for a chronic lung disease ...
Plus, news about Caliway Biopharmaceuticals, Orca Bio, Alterity Therapeutics and...
Roche's $8 billion InterMune acquisition, disclosed a decade ago, is now being h...
Pliant Therapeutics has slammed the brakes on enrollment and dosing in a mid-sta...
Plus, news about X4 Pharmaceuticals, Viracta Therapeutics, Crown Laboratories, Q...
It took one month for Johnson & Johnson to secure its $14 billion acquisition of...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential ne...
AstraZeneca has terminated all development of vemircopan, the oral factor D inhi...
We’re in dealmaking season for publicly traded digital health companies. In ...
Almost 16 years after Rituxan's disappointing data in lupus, Roche's Genentech f...
A trade group representing 1,600 hospitals says 340B rebate models proposed by m...
After promoting its oncology officer Chris Boshoff to chief scientific officer l...
Personify Health, which sells healthcare spending management services to employe...